Michael Christoph FrÃ¼hwald

List of Publications by Year
in descending order

79 papers	7,207 citations	147801 31 h-index	74163 75 g-index
81 all docs	81 docs citations	81 times ranked	9593 citing authors

#	Article	IF	Citations
1	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
2	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
3	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
4	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
5	Germline Nonsense Mutation and Somatic Inactivation of SMARCA4/BRG1 in a Family with Rhabdoid Tumor Predisposition Syndrome. American Journal of Human Genetics, 2010, 86, 279-284.	6.2	288
6	Next-generation personalised medicine for high-risk paediatric cancer patients â€“ The INFORM pilot study. European Journal of Cancer, 2016, 65, 91-101.	2.8	262
7	Atypical teratoid/rhabdoid tumorsâ€”current concepts, advances in biology, and potential future therapies. Neuro-Oncology, 2016, 18, 764-778.	1.2	185
8	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	30.7	172
9	SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. Acta Neuropathologica, 2014, 128, 453-456.	7.7	155
10	Highâ€resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes and Cancer, 2013, 52, 185-190.	2.8	138
11	Molecular subgrouping of atypical teratoid/rhabdoid tumorsâ€”a reinvestigation and current consensus. Neuro-Oncology, 2020, 22, 613-624.	1.2	133
12	Frequency, Riskâ€Factors and Survival of Children With Atypical Teratoid Rhabdoid Tumors (AT/RT) of the CNS Diagnosed between 1988 and 2004, and Registered to the German HIT Database. Pediatric Blood and Cancer, 2011, 57, 978-985.	1.5	121
13	Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor. Genes Chromosomes and Cancer, 2010, 49, 176-181.	2.8	96
14	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. Cell Reports, 2019, 29, 2338-2354.e7.	6.4	74
15	Improved 6â€year overall survival in <scp>AT</scp>/<scp>RT</scp> â€“ results of the registry study Rhabdoid 2007. Cancer Medicine, 2016, 5, 1765-1775.	2.8	73
16	Age and DNA methylation subgroup as potential independent risk factors for treatment stratification in children with atypical teratoid/rhabdoid tumors. Neuro-Oncology, 2020, 22, 1006-1017.	1.2	72
17	Non-linkage of familial rhabdoid tumors toSMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome. Pediatric Blood and Cancer, 2006, 47, 273-278.	1.5	65
18	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	16.8	65

#	Article	IF	Citations
19	Rhabdoid tumors in children: prognostic factors in 70 patients diagnosed in Germany. Oncology Reports, 2008, 19, 819-23.	2.6	65
20	High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB). Bone Marrow Transplantation, 2014, 49, 370-375.	2.4	58
21	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1â€deficient nonâ€rhabdoid tumor with favorable longâ€term outcome. Brain Pathology, 2017, 27, 411-418.	4.1	58
22	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. European Journal of Cancer, 2019, 114, 27-35.	2.8	51
23	Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. Pediatric Hematology and Oncology, 2017, 34, 231-237.	0.8	47
24	Emerging therapeutic targets for the treatment of malignant rhabdoid tumors. Expert Opinion on Therapeutic Targets, 2018, 22, 365-379.	3.4	46
25	Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1. International Journal of Cancer, 2014, 135, 989-995.	5.1	42
26	BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors. International Journal of Molecular Sciences, 2017, 18, 1537.	4.1	42
27	Next-generation reference intervals for pediatric hematology. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1595-1607.	2.3	42
28	Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). Pediatric Blood and Cancer, 2014, 61, 919-921.	1.5	41
29	Strategies to improve the quality of survival for childhood brain tumour survivors. European Journal of Paediatric Neurology, 2015, 19, 619-639.	1.6	36
30	Highâ€dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survivalâ€”The Gesellschaft fÃ¼r PÃdiatrische Onkologie und HÃmatologie (GPOH) experience. Pediatric Blood and Cancer, 2018, 65, e26746.	1.5	35
31	Feasibility of Intensive Multimodal Therapy in Infants Affected by Rhabdoid Tumors â€“ Experience of the EU-RHAB registry. Klinische Padiatrie, 2014, 226, 143-148.	0.6	33
32	Rhabdoid Tumors: Clinical Approaches and Molecular Targets for Innovative Therapy. Pediatric Hematology and Oncology, 2013, 30, 587-604.	0.8	30
33	Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis. European Journal of Human Genetics, 2018, 26, 1083-1093.	2.8	30
34	Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumorâ€”feasibility and efficacy of multimodal therapy in a long-term survivor. Cancer Genetics, 2014, 207, 429-433.	0.4	28
35	Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging. Clinical Cancer Research, 2004, 10, 2997-3006.	7.0	27
36	Tumors of the Central Nervous System in Children and Adolescents. Deutsches Ärzteblatt International, 2011, 108, 390-7.	0.9	27

#	Article	IF	Citations
37	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
38	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	1.2	25
39	Bone Involvement in Atypical Teratoid/Rhabdoid Tumors of the CNS. American Journal of Neuroradiology, 2013, 34, 2039-2042.	2.4	24
40	Macrophage-tumor cell interaction promotes ATRT progression and chemoresistance. Acta Neuropathologica, 2020, 139, 913-936.	7.7	24
41	Limbic encephalitis with LGI1 antibodies in a 14-year-old boy. European Journal of Paediatric Neurology, 2018, 22, 190-193.	1.6	22
42	Sickle cell disease in Germany: Results from a national registry. Pediatric Blood and Cancer, 2020, 67, e28130.	1.5	20
43	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	1.9	20
44	Infantile Fibrosarcomaâ€"An Important Differential Diagnosis of Congenital Vascular Tumors. Pediatric Hematology and Oncology, 2012, 29, 545-548.	0.8	19
45	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. Neuro-Oncology, 2021, 23, 1012-1023.	1.2	19
46	Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group. Cytotherapy, 2016, 18, 1178-1186.	0.7	18
47	DNA Methylation Patterns in Cancer. Molecular Diagnosis and Therapy, 2003, 3, 245-260.	3.3	17
48	The Epigenetics of Cancer in Children. Klinische Padiatrie, 2008, 220, 333-341.	0.6	17
49	Age, American Thyroid Association Risk Group, and Response to Therapy Are Prognostic Factors in Children With Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e165-e177.	3.6	17
50	Sensitivity of fineâ€needle biopsy in detecting pediatric differentiated thyroid carcinoma. Pediatric Blood and Cancer, 2012, 59, 233-237.	1.5	16
51	The extraordinary challenge of treating patients with congenital rhabdoid tumorsâ€"a collaborative European effort. Pediatric Blood and Cancer, 2018, 65, e26999.	1.5	15
52	Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). European Journal of Cancer, 2021, 142, 112-122.	2.8	15
53	Claudinâ€6 is of Limited Sensitivity and Specificity for the Diagnosis of Atypical Teratoid/Rhabdoid Tumors. Brain Pathology, 2011, 21, 558-563.	4.1	14
54	Malignant rhabdoid tumor of the kidney: significantly improved response to pre-operative treatment intensified with doxorubicin. Cancer Genetics, 2014, 207, 434-436.	0.4	14

#	Article	IF	Citations
55	Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system. Journal of Neuro-Oncology, 2014, 116, 237-249.	2.9	13
56	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. Child's Nervous System, 2013, 29, 1253-1262.	1.1	12
57	Spinal cord atypical teratoid/rhabdoid tumors in children: Clinical, genetic, and outcome characteristics in a representative European cohort. Pediatric Blood and Cancer, 2020, 67, e28022.	1.5	12
58	Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors. Cancer Management and Research, 2022, Volume 14, 479-498.	1.9	11
59	Infants and Newborns with Atypical Teratoid Rhabdoid Tumors (ATRT) and Extracranial Malignant Rhabdoid Tumors (eMRT) in the EU-RHAB Registry: A Unique and Challenging Population. Cancers, 2022, 14, 2185.	3.7	9
60	Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S. Pediatric Hematology and Oncology, 2017, 34, 17-23.	0.8	7
61	How I approach hereditary cancer predisposition in a child with cancer. Pediatric Blood and Cancer, 2019, 66, e27916.	1.5	7
62	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. Acta Neuropathologica, 2019, 137, 847-850.	7.7	7
63	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. BMC Pharmacology & Toxicology, 2020, 21, 37.	2.4	7
64	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. Pediatric Blood and Cancer, 2021, 68, e29267.	1.5	7
65	Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB). Cancer Genetics, 2014, 207, 379-383.	0.4	6
66	Revisiting the genotypeâ€•phenotype correlation in children with medullary thyroid carcinoma: A report from the GPOHâ€MET registry. Pediatric Blood and Cancer, 2020, 67, e28171.	1.5	6
67	Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK). International Journal of Radiation Oncology Biology Physics, 2020, 108, 667-675.	0.8	6
68	Nutritional status of children and young adults with Ewing Sarcoma or osteosarcoma at diagnosis and during multimodality therapy. Pediatric Blood and Cancer, 2013, 60, 166-166.	1.5	5
69	Effectiveness of a Psychosocial Aftercare Program for Youth Aged 8 to 17 Years With Severe Chronic Pain. JAMA Network Open, 2021, 4, e2127024.	5.9	5
70	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18Âmonths without MYCN amplification. Pediatric Blood and Cancer, 2021, 68, e29038.	1.5	4
71	Long-term survival of an infant with an atypical teratoid/rhabdoid tumor following subtotal resection and low-cumulative dose chemotherapy: a case report. Child's Nervous System, 2016, 32, 1157-1161.	1.1	3
72	Rapid Diagnosis of an AT/RT by the Detection of a Heterozygous SMARCB1 Germ Line Deletion in an Infant. Pediatric Blood and Cancer, 2016, 63, 1451-1453.	1.5	1

#	Article	IF	Citations
73	A Retrospective 5-Year Single Center Study Highlighting the Risk of Cancer Predisposition in Adolescents and Young Adults. Cancers, 2021, 13, 3033.	3.7	1
74	Exploring the Mechanisms Underlying the Effectiveness of Psychosocial Aftercare in Pediatric Chronic Pain Treatment: A Qualitative Approach. Children, 2022, 9, 407.	1.5	1
75	ATRT-15. SPINAL CORD ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) IN CHILDREN: RESULTS OF A EUROPEAN RETROSPECTIVE ANALYSIS UNDER THE AUSPICES OF THE EU-RHAB STUDY GROUP. Neuro-Oncology, 2018, 20, i30-i30.	1.2	0
76	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
77	Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient. Anticancer Research, 2020, 40, 6159-6170.	1.1	0
78	ATRT-12. LIN28A expression correlates with poor prognosis and the MYC subgroup in AT/RTs. Neuro-Oncology, 2022, 24, i5-i5.	1.2	0
79	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0